1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Capital Structure
3. What does Scribe Therapeutics, Inc. do?
4. Valuation
5. 𝕏 Posts
Discussion
Symbol
SCTX
Event Date
2026-07-24
Sector
Health Care
Subsector
Biotechnology
Offer Range
$15.00
Shares Offered
8.58M
Shares Outstanding Pre-IPO
13.41M
21.1M
$316.5M
40.7%
Implied Upside vs Midpoint
Description
We are a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. While current genetic medicines are largely limited to rare disorders, we are engineering our technologies for use in common diseases affecting millions. By targeting prevalent diseases with significant unmet need and high clinical burden, we aim to usher in a new era of broadly scalable, transformative, and preventative genetic medicines. Our focus is on cardiovascular and metabolic diseases with initial programs to address the key drivers of atherosclerotic cardiovascular disease, or ASCVD. We are designing CRISPR-based genetic medicines to be well-tolerated, effective, durable, and scalable enough to shift the treatment paradigm from symptom-driven intervention and chronic care to population-level prevention, with the goal of broadly democratizing access to the cardioprotective effects of known genetic variants. Our lead product candidate, STX-1150, utilizes ELXR, our highly engineered epigenetic silencing technology, and is designed to deliver persistent and potent LDL-C reductions without permanent genetic changes. STX-1150 is a demonstration of moving towards our goal to transform practical therapeutic adherence and real-world medical outcomes for patients in the multibillion-dollar LDL-C lowering landscape. We have secured regulatory clearance from the Australian Therapeutic Goods Administration, or TGA, for and initiated a first-in-human clinical trial of STX-1150 in Australia in up to 64 adults with elevated LDL-C and increased risk of ASCVD. We anticipate reporting initial data from this trial, including safety, tolerability, and LDL-C-lowering activity, in the first half of 2027. Every 40 seconds, someone in the United States suffers a heart attack, and each year, heart disease costs the nation more than $400 billion, according to the American Heart Association. Despite major advances in our understanding of the pathology of heart disease and ASCVD, and the development of new classes of pharmaceuticals, we believe today’s standard of care for ASCVD is insufficient. Existing treatments fail to demonstrate broad real-world impact due to limitations in efficacy, well-documented side effects, and the burden of chronic polypharmacy, which all contribute to poor uptake, low adherence, and limited persistence. Similarly, patients often discontinue therapy due to the lifelong burden of taking medication, loss of insurance, high out-of-pocket costs, or the logistical burden of ongoing clinic visits. Moreover, treatment is often initiated only after substantial cumulative arterial injury or an acute cardiovascular event. These limitations of the current treatment paradigms underscore the importance of developing effective and durable therapies that can be administered safely early in the course of disease, reduce the barriers to treatment continuation for patients, and provide compelling health-economic value to payors. We believe that a fundamentally different approach is required to meaningfully treat or prevent ASCVD. We must create practical, optimized therapies that remain effective even when used early in disease progression. To realize this vision, we are executing a differentiated strategy that applies a full-stack engineering approach coupling generative artificial intelligence and machine learning, with massively parallel experimental validation to optimize and tailor CRISPR technologies for the precise demands of each therapeutic application. Through this proprietary approach, which we refer to as CRISPR by Design, we systematically evaluate disease biology, target genetics, and commercial opportunities against product requirements to engineer the most appropriate and scalable solution for each therapeutic application. This disciplined, data-driven strategy has led us to engineer two proprietary technologies based on a novel CRISPR-CasX enzyme: the Epigenetic Long-Term X-Repressor, or ELXR, designed for precise, durable epigenetic silencing without altering the underlying DNA sequence; and the X-Editor, or XE, designed for specific and efficient gene editing. When developing a program, rather than committing to a single technology upfront, we advance multiple approaches in parallel and prioritize the modality that demonstrates the most favorable safety, durability, and efficacy profile for each product candidate based on empirical data. We believe this engineering-led, evidence-based strategy, combined with a technology stack purpose-built for broad patient populations, positions us to develop competitive and scalable genetic medicines across a wide range of cardiovascular indications. We are advancing three in vivo product candidates targeting three key lipid drivers of ASCVD: elevated low-density lipoprotein cholesterol, or LDL-C, elevated lipoprotein(a), or Lp(a), and elevated triglycerides carried by triglyceride-rich lipoproteins, or TRLs. Our lead product candidate, STX-1150, is an epigenetic silencing therapy that is based on our ELXR technology and is designed to durably lower LDL-C by repressing the expression of PCSK9, a genetically and clinically validated target. Inhibition of PCSK9 is among the most effective known mechanisms to reduce LDL-C, complementing or outperforming other existing therapies. Unlike CRISPR gene editing, base editing, or prime editing approaches, STX-1150 is designed to achieve long-lasting therapeutic benefit without permanently altering underlying DNA sequence. STX-1150 aims to improve on the real-world efficacy of small-molecule, antibody, and siRNA therapies by eliminating the need for years to decades of chronic medication. In a study conducted with non-human primates, or NHPs, a single dose of a prototype STX-1150 was generally well-tolerated and produced therapeutically meaningful, durable LDL-C reduction of greater than 50% sustained for two years. Durable and early LDL-C lowering of this magnitude has been demonstrated in human genetic studies to reduce ASCVD risk by up to 88%, underscoring the potential to transform the current treatment paradigms from late-stage intervention to effective prevention. The large and expanding LDL-C lowering market is characterized by a persistent gap between efficacy observed in controlled settings and real-world outcomes. We believe STX-1150’slong-acting epigenetic mechanism could increase current adherence rates that are typically only 40–50%, which could drive superior clinical outcomes for patients through increased adherence-adjusted efficacy and compelling health-economic value for payors while avoiding the risks of permanent genetic modification. Given that ASCVD is a chronic condition, we believe providing patients with improvements in practical adherence could compound over time to drive better clinical outcomes, enabling more efficient payor management and broadening patient access. As a result, we believe STX-1150 has the potential to expand the growing market for PCSK9-based LDL-C–lowering medicines, which currently exceeds $5 billion annually yet remains significantly underpenetrated, with fewer than 1% of eligible patients treated. We have secured regulatory clearance from the Australian TGA for and initiated a first-in-human clinical trial of STX-1150 in Australia in up to 64 adults with elevated LDL-C and increased risk of ASCVD. We anticipate reporting initial data from this trial, including safety, tolerability, and LDL-C-lowering activity, in the first half of 2027. Our next programs, STX-1200 and STX-1400, target two additional lipid drivers of ASCVD, elevated Lp(a) and severely high triglycerides, by editing the LPA and APOC3 genes, respectively. Elevated Lp(a) and high triglycerides represent key risk factors for ASCVD affecting large populations. Both programs are based on our XE technology and aim to provide curative solutions for genetic diseases associated with the modification of these targets. In mouse models of disease, prototype versions of both STX-1200 and STX-1400 programs have achieved greater than 90% reduction in target gene expression with durable effect consistent with a one-time treatment profile. In NHPs, surrogates demonstrated greater than 95% Lp(a) reduction and greater than 75% APOC3 on-target editing. In an off-target analysis of primary human hepatocyte donor cells, no detectable off-target editing was observed even at supersaturating doses. We have been awarded grant funding from the California Institute for Regenerative Medicine, or CIRM, of up to approximately $25.7 million to support the development and manufacturing activities for our STX-1200 and STX-1400 programs. With CIRM funding support, we anticipate continuing to advance both the STX-1200 and STX-1400 programs through preclinical development to enable the initiation of a Phase 1 clinical trial for one of these programs as early as 2027 and one in 2028. --- Our disciplined operating model, complemented by upfront and milestone payments from our strategic collaborations and grants, has allowed us to operate with a high degree of capital efficiency. We believe our CRISPR by Design approach enables us to advance target concepts to development candidates quickly, with the potential to materially reduce discovery timelines and associated costs. Our strategic collaborations – including with Sanofi in rare genetic diseases, such as sickle cell disease, and Lilly in neurological and neuromuscular disorders – leverage the commercial and delivery expertise of leading biopharmaceutical companies while demonstrating the versatility of our technologies. Since our founding in 2017, we have raised approximately $150.0 million in equity financing, with only one dilutive financing in the past four years, while maintaining significant ownership and optionality across both our internal program portfolio and our collaboration programs. Since the groundbreaking discovery of CRISPR-based genome editing by our co-founder, Nobel Laureate Dr. Jennifer Doudna, the extraordinary potential for genetic medicine has become increasingly clear. We were founded on the thesis that comprehensive CRISPR system engineering and optimization are required to address the activity, specificity, and delivery limitations of earlier technologies. We believe our engineering-first philosophy has enabled us to become one of the only companies that has created two distinct, novel and therapeutically relevant CRISPR technologies derived from a unique CRISPR enzyme foundation. This foundation, together with our enabling engineering, supports a robust intellectual property portfolio. Our deliberate focus on cardiovascular and metabolic diseases further differentiates us by driving the creation of technologies designed to address some of the most prevalent and debilitating conditions worldwide. --- We were incorporated under the laws of the State of Delaware on June 30, 2017. Our principal executive offices are located at 1150 Marina Village Parkway, Alameda, California 94501, and our telephone number is (510) 626-8587. Our website address is https://www.scribetx.com.
Post-IPO economic shares by class, valued at the offer midpoint.
| Class | Shares | % Economic | Est. value |
|---|---|---|---|
Common Stock (listed) 1 vote per share · none | 16.18M | 76.7% | $242.7M |
Redeemable Convertible Preferred Stock Converts to common stock · Automatically converts at a ratio of 0.1689 | 4.92M | 23.3% | $73.7M |
| Total economic shares | 21.1M | 100% | $316.5M |
Scribe Therapeutics plans to raise around $100M in its IPO by offering 7.15M shares at $13-$15 each, promoting its lead candidate STX-1150 targeting LDL-C reduction without permanent DNA edits.
AI per-post analysis: 0 positive, 0 negative, 2 neutral (engagement-weighted aggregate).